Windtree Therapeutics Heart Failure Drug Candidate Improves Systolic Blood Pressure

By Yahoo! Finance | Sep 25, 2024 at 09:40 AM EST

Windtree Therapeutics announced positive Phase 2b results for istaroxime in treating cardiogenic shock. The study showed improvement in blood pressure and cardiac function over 96 hours, with promising safety. Detailed results will be presented at the Heart Failure Society of America Meeting in September.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.